SCHEMBL1504713

SCHEMBL1504713

CONC(=O)c1ccc(Cl)c(NC(=O)c2ccc(=O)n(-c3c(Cl)cccc3Cl)c2)c1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 6/20 0.46
HDAC8 Q9BY41 6/20 0.46
HDAC6 Q9UBN7 6/20 0.46
CYP1A2 P05177 3/20 0.45
CYP3A4 P08684 2/20 0.45
KMT2A Q03164 2/20 0.45
POLB P06746 1/20 0.44
PDE4D Q08499 1/20 0.44
CYP2C19 P33261 2/20 0.43
CYP2C9 P11712 1/20 0.43
F10 P00742 1/20 0.42
KDM4E B2RXH2 3/20 0.42
ALDH1A1 P00352 2/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
CYP2D6 P10635 1/20 0.41
LMNA P02545 1/20 0.41
MEN1 O00255 1/20 0.41
HPGD P15428 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1504505 0.85 HDAC1 (0.48) HDAC1HDAC8HDAC6CYP1A2KMT2A
SCHEMBL1504536 0.85 CYP1A2 (0.53) HDAC1HDAC8HDAC6CYP1A2KMT2A
SCHEMBL1504630 0.82 KDM4E (0.52) HDAC1HDAC8HDAC6CYP1A2KMT2A
SCHEMBL1504004 0.81 MAPK8 (0.50) HDAC1HDAC8HDAC6CYP1A2CYP3A4
SCHEMBL1504561 0.81 NPC1 (0.50) HDAC1HDAC8HDAC6F10SMN1; SMN2
SCHEMBL1504516 0.80 SMN1; SMN2 (0.52) HDAC1HDAC8HDAC6KMT2AKDM4E
SCHEMBL1504540 0.80 NPC1 (0.52) KMT2AF10KDM4EALDH1A1SMN1; SMN2
SCHEMBL1504623 0.79 MAPK14 (0.43) HDAC1HDAC8HDAC6CYP1A2KMT2A
SCHEMBL1504507 0.79 HDAC1 (0.44) HDAC1HDAC8HDAC6CYP3A4KMT2A
SCHEMBL1504668 0.78 HDAC1 (0.42) HDAC1HDAC8HDAC6CYP1A2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8173684-B2 Pyridone derivatives as p38α MAPK inhibitors ASTELLAS PHARMA INC. (JP) 2012-05-08 US disclosed
US-8173684-B2 Pyridone derivatives as p38α MAPK inhibitors ASTELLAS PHARMA INC. (JP) 2012-05-08 US disclosed
US-8173684-B2 Pyridone derivatives as p38α MAPK inhibitors ASTELLAS PHARMA INC. (JP) 2012-05-08 US disclosed
EP-2155683-B1 PYRIDONE DERIVATIVES AS P38A MAPK INHIBITORS ASTELLAS PHARMA INC (JP) 2011-03-16 EP disclosed
US-20100063098-A1 PYRIDONE DERIVATIVES AS P38A MAPK INHIBITORS ASTELLAS PHARMA INC. (JP) 2010-03-11 US disclosed
US-20100063098-A1 PYRIDONE DERIVATIVES AS P38A MAPK INHIBITORS ASTELLAS PHARMA INC. (JP) 2010-03-11 US disclosed
US-20100063098-A1 PYRIDONE DERIVATIVES AS P38A MAPK INHIBITORS ASTELLAS PHARMA INC. (JP) 2010-03-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100063098-A1 PYRIDONE DERIVATIVES AS P38A MAPK INHIBITORS MAPK1, MAPK6, MAPK3 HDAC1 777/4885HDAC8 1531/4885HDAC6 2198/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.